Comparison of 60 or 90 mg/m2 of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics

Publisher: John Wiley & Sons Inc

E-ISSN: 1096-8652|90|2|E29-E30

ISSN: 0361-8609

Source: AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.2, 2015-02, pp. : E29-E30

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract